Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Kymera Therapeutics (KYMR) PT Lowered to $70 at Brookline Capital Markets
June 25, 2025 4:05 PM EDTBrookline Capital Markets analyst Leah Rush Cann lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $70.00 (from $97.00) while maintaining a Buy rating.
The analyst comments "Conclusions Our estimated revenue for 2025 2027 is being reduced resulting from timing of collaboration revenue from Sanofi. We have... More
Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
June 25, 2025 12:43 PM EDTJefferies analyst Kelly Shi lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $64.00 (from $66.00) while maintaining a Buy rating.
The analyst comments "KYMR announced two updates on parternship: 1) SNY will not advance Ph2 IRAK4 degrader KT-474 in AD/HS and will... More
Stifel says buy Kymera Therapeutics (KYMR) on today's weakness
June 25, 2025 10:32 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR), saying they would buy on today's weaknesses related to the updated on the Sanofi IRAK4 collaboration. Shares of KYMR are down 3.7% currently.
The analyst commented, "We are reiterating our Buy Rating on... More
